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Department of Statistical Science, University College London, London, UKA B S T R A C TObjective: The expected value of sample information (EVSI) quantiﬁes
the economic beneﬁt of reducing uncertainty in a health economic
model by collecting additional information. This has the potential to
improve the allocation of research budgets. Despite this, practical EVSI
evaluations are limited partly due to the computational cost of
estimating this value using the gold-standard nested simulation
methods. Recently, however, Heath et al. developed an estimation
procedure that reduces the number of simulations required for this
gold-standard calculation. Up to this point, this new method has been
presented in purely technical terms. Study Design: This study
presents the practical application of this new method to aid its
implementation. We use a worked example to illustrate the key steps
of the EVSI estimation procedure before discussing its optimal imple-
mentation using a practical health economic model. Methods: The
worked example is based on a three-parameter linear health economic
model. The more realistic model evaluates the cost-effectiveness of aee front matter Copyright & 2018, ISPOR–The Pro
r Inc. This is an open access article under the CC
16/j.jval.2018.05.004
pondence to: Anna Heath, Department of Statis
UK.
th.14@ucl.ac.uknew chemotherapy treatment, which aims to reduce the number of
side effects experienced by patients. We use a Markov model structure
to evaluate the health economic proﬁle of experiencing side effects.
Results: This EVSI estimation method offers accurate estimation
within a feasible computation time, seconds compared to days, even
for more complex model structures. The EVSI estimation is more
accurate if a greater number of nested samples are used, even for a
ﬁxed computational cost. Conclusions: This new method reduces the
computational cost of estimating the EVSI by nested simulation.
Keywords: health economic evaluations, probabilistic sensitivity
analysis, sample information, trial design, value of information.
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The expected value of sample information (EVSI) [1] uses evi-
dence about the cost and effectiveness of new treatments to
determine the expected economic beneﬁt of undertaking a
proposed study [2]. The EVSI calculates this value by determining
the extent to which the additional information from the study
reduces the probability and expected loss of making inefﬁcient
treatment recommendations [3]. In general, an inefﬁcient recom-
mendation would spend health resources that would be used to
improve patient outcomes elsewhere. In addition, information
from future studies has the potential to improve patient out-
comes within the disease area under investigation.
As the EVSI calculates the value of a speciﬁc trial, it has the
potential to be used to determine the optimal allocation of
research funding. Despite this, the EVSI has rarely been used in
practical scenarios [4]. This is partly due to the large computa-
tional effort required to calculate the EVSI using the gold-
standard nested Monte Carlo method [2].
Recently, a number of methods have been developed to reduce
the computation time for the EVSI [5–10]. While computationallyefﬁcient, these methods require the use of additional statistical
techniques, for example, specifying sufﬁcient statistics [11], and
may impose restrictions on the underlying economic model. There-
fore, EVSI calculations have been repeatedly undertaken using
Monte Carlo procedures, either using approximations to avoid
nested simulations [12–14] or with high computational cost [15–18].
Using nested Monte Carlo methods is advantageous as it can
be used irrespective of the complexity of the economic model. In
addition, the EVSI is often understood in terms of this nested
Monte Carlo estimation procedure [5,8,19,20], making the com-
putation method easier to comprehend. To utilize these advan-
tages, Heath et al. [10]developed a computationally efﬁcient EVSI
calculation method based solely on nested sampling to calculate
the EVSI in all practical scenarios, within a reasonable timeframe.
The validity of this method has been demonstrated elsewhere
[10] and thus this paper is focused on presenting its practical
implementation. The Formal deﬁnition of the EVSI section
introduces the EVSI, key notation, and the nested Monte Carlo
method. The section The moment matching method outlines
the efﬁcient Monte Carlo method using a simple toy. Finally,
the Calculating the EVSI section investigates the optimal choicefessional Society for Health Economics and Outcomes Research.
BY license (http://creativecommons.org/licenses/by/4.0/).
tical Science, University College London, 1-19 Torrington Place,
V A L U E I N H E A L T H 2 1 ( 2 0 1 8 ) 1 2 9 9 – 1 3 0 41300of the key input for this efﬁcient Monte Carlo method using
an economic model evaluating a new chemotherapy treatment
[21].Formal Deﬁnition of the EVSI
In general, information has value as it reduces uncertainty in
the inputs of a health economic model, denoted θ. Therefore, to
calculate the EVSI, we must model the current level of uncer-
tainty in θ using probability distributions that indicate the most
plausible range for these inputs. This is performed as part of a
probabilistic sensitivity analysis (PSA) [22,23], where the param-
eters of these distributions are usually informed by literature
reviews alongside clinical trials and expert opinion.
To value each of the treatment options, normally using a net
beneﬁt function [24], the model inputs are combined using an
economic model. To ease our explanation, we assume through-
out that this economic model compares only two treatment
options—typically, an innovative treatment and the standard of
care. The output of the economic model is then the incremental
net beneﬁt (INB), that is, the difference between the net
beneﬁt of the innovative treatment and net beneﬁt of the
standard of care. In this setting, uncertainty in the model inputs
implies that the INB is also uncertain. From this, we conclude
that the innovative treatment is optimal if the average INB
is greater than 0, and the standard of care is optimal
otherwise [22].
Figure 1 presents a pictorial description of the EVSI; the top
panel shows the PSA process where the value of the optimal
treatment is some monetary value, say $C. To calculate the EVSI,
we consider that additional information, denoted by X, is going to
be collected in a future study, for example, a clinical trial or an
observational study, to reduce the uncertainty in some of the
model inputs. If X had been collected, that is, the future study
had already been conducted, then the decision-making process
would be exactly as we have already described. The information
in X would be formally included in the PSA distributions and the
value of the optimal decision given this additional information
would be either 0 (if the average INB is negative) or the average
INB itself, which is equal to $F in the bottom of Figure 1.
Comparing $F with $C gives the value of the sample information
(VSI)
In general, we can consider the PSA distributions to be the
prior for θ, which is, using the Bayes theorem, combined with theFig. 1 – A graphical representation of the process underlying
the EVSI. The top panel represents the current decision
making process, based on some model inputs and a given
economic model. The bottom panel indicates one possible
future decision making process, derived by additional
information X obtained from a potential study and based on
the same economic model.data X to compute the posterior distribution for θ. This in turn
implies a posterior distribution for the INB.
However, as the future study has not been run (and poten-
tially will never be), we deﬁne a distribution over the possible, yet
unknown, study outcomes. The EVSI is then equal to the average
VSI over all these possible future datasets. Mathematically, it can
be expressed in terms of the INB as
EVSI¼EX max 0,EθjX INB½ 
  max 0,Eθ INB½  
where EθjX½INB is the posterior expectation of the INB for a
speciﬁc sample X. Typically, X will only directly update a small
number of model parameters, but in a Bayesian setting we still take
expectation with respect to the joint posterior distribution pðθjXÞ.
To model the possible study outcomes, we specify the sam-
pling distribution for the data, had they been collected. This will
depend on some of the model inputs; for example, a binomial
distribution models the number of people responding to a treat-
ment conditional on the success rate of the drug. Combining this
sampling distribution, conditional on the model inputs, with the
PSA distributions for the model inputs gives a distribution over
the potential future datasets. This process is represented by the
red arrow in Figure 1.
PSA is normally undertaken using a simulation approach
[21,22,25], where S simulations are taken from the distribution
of the model inputs. Each of these simulations is then fed
through the economic model to calculate S simulations from
the distribution of the INB, denoted INBs for s¼1,…,S:
To calculate the EVSI, a potential future dataset, denoted Xs , is
then simulated for each PSA simulation s¼1,…,S: This
uses the sampling distribution for X conditional on a subset of
the model inputs. Each of these simulated datasets is used to ﬁnd
the posterior for the model inputs and thus the posterior of the
INB. In the most general setting, this updating uses Monte Carlo
methods, particularly Markov Chain Monte Carlo (MCMC) meth-
ods. This means that R simulations are taken from the posterior
distribution of the model inputs to calculate the average INB.
Consequently, to calculate the EVSI by Monte Carlo requires
S  R simulations, which can be relatively computationally
expensive for standard choices of S (normally around 1000) and
R (at least 600 [26]).
The method presented in this paper uses a nested Monte
Carlo scheme but ﬁnds the posterior distribution of the model
inputs for a small number of potential future datasets. Speciﬁ-
cally, the required number of posterior updates reduces from S to
Q o 100. This maintains the ﬂexibility of the nested Monte Carlo
method while drastically reducing its computational cost, irre-
spective of the model structure.The Moment Matching Method
The efﬁcient nested Monte Carlo method [10] is based on
“moment matching” and requires several elements. To begin,
we must estimate the mean μθ and variance σ2θ of the INB, using
the PSA simulations.
Uncertainty due to Key Parameters
As previously discussed, the sampling distribution of X typically
depends directly on a small number of the model inputs. For
example, within a full health economic model, a clinical trial
would focus on the epidemiological parameters and not the
economic disease burden. To formalize this, we assume that
the model inputs split into two categories, ϕ,ψð Þ, where the
sampling distribution for X is based solely on the inputs ϕ (e.g.,
the epidemiological parameters) and all the remaining inputs are
in ψ. The moment matching method requires the distribution of
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marginalized out. This is expressed mathematically as
INBϕ¼Eψjϕ INB ϕ,ψð Þ½ :
Notice that this quantity is required to calculate an alternative
value of information measure known as the expected value of
partial perfect information (EVPPI) [6], which quantiﬁes the
economic value of learning the exact value of the model inputs
ϕ. If the data provided by the study cannot give exact informa-
tion, the EVPPI for ϕ is an upper bound for the EVSI. If this upper
bound is low, then there is no value in a study targeting ϕ, and so
the modeler can discount a trial targeting ϕ before determining a
sampling distribution for X. Therefore, the EVPPI should always
be calculated before proceeding to the EVSI [27,28], which means
that the INBϕ values should already be available. Several methods
have been developed to estimate the EVPPI [10,29,30] and, more
importantly, general purpose software is available to calculate
INBϕ directly from the PSA simulations [31–33].
The Nested Posterior Variance
The ﬁnal element required to estimate the EVSI is the variance of
the posterior INB across different possible future samples. The
variance of the posterior INB is inversely proportional to the EVSI.
This is because the decision between the two treatment options
becomes more certain as the posterior variance of the INB
decreases.
To estimate the expected variance of the posterior INB, we
used a nested Monte Carlo method. This is the same process as
the gold-standard EVSI estimation method, where potential data-
sets are simulated conditionally on some values for ϕ and used
to ﬁnd posteriors for the model inputs using MCMC. The eco-
nomic model is then used to calculate posterior distributions of
the INB using simulations for the model inputs. The only differ-
ence between the two methods is that the moment matching
method requires an estimate of the variance of the posterior INB,
rather than its mean.
To accurately estimate the EVSI, the variance of the posterior
INB must be estimated for a number of potential datasets, say Q.
Theoretically, Q should be greater than 30 because accurate
estimation of the variance depends on the central limit theorem,
but the variance of the posterior INB is sufﬁciently accurate for
values of Q close to 30 [10], provided that the future datasets are
simulated using the following procedure.
Loosely, we want to “space-out” the simulated future datasets
to accurately estimate the EVSI. To achieve this, we ﬁnd Q equally
spaced values of ϕ by determining the quantiles of the PSA
simulations and use these to generate the future datasets. Practi-
cally, we proceed by ordering the PSA simulations for each of the
model inputs in ϕ and selecting the qQþ1
th elements in these
ordered lists for ¼ 1,…,Q. For example, if Q ¼ 3 and the number of
PSA simulations S ¼ 1000, then each column in ϕ should be
ordered and the 250th, 500th, and 750th elements from each of
these lists should be selected.
For each selected row in the ordered ϕ list, we simulate one
potential future sample from the sampling distribution of X.
These potential future samples are each used to ﬁnd a posterior
distribution for the model inputs using MCMC. A posterior
distribution for the INB is calculated for each of the samples
and the variance, denoted σ2q for when q ¼ 1,...,Q, is calculated.
Calculating the EVSI
To calculate the EVSI, we must combine the following different
elements:
1. The mean of the INB from the PSA simulations μθ;
2. The variance of the INB from the PSA simulations σ2ϕ;3. The INBϕ values used to calculate the EVPPI;
4. The variance of theINBϕ values, denoted σ2θ ;
5. The posterior variance of the INB calculated Q times using
nested sampling σ2q for q ¼ 1,…,Q.
First, we calculate the average posterior variance across the Q
nested samples:
σ2X¼
1
Q
XQ
q¼1
σ2q:
Finally, the previous elements are used to rescale the INBϕ
values:
INBn¼ INBϕμθﬃﬃﬃﬃﬃ
σ2ϕ
q
0
B@
1
CA ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃσ2θ σ2Xq þ μθ:
This gives S rescaled INBϕ values, where S is the number of
PSA simulations, which are then used to estimate the EVSI:
dEVSI¼ 1
S
XS
s¼1
max 0,INBns
 max 0,μθ 
Toy Example
To clarify the moment matching method, we estimate the EVSI in
a very simple setting. The effectiveness measure in this example
is the probability of curing a disease. Information from a previous
trial implies that the uncertainty in this effectiveness measure
for two treatments under consideration can be modeled using the
following beta distributions: 1) π1Betað3,4Þ and 2) π2Betað4,3Þ. A
literature review determines that uncertainty in the incremental
cost can be modeled using a normal distribution, such as
δNormal ð3,20Þ. Therefore, in this example, θ¼ðπ1,π2,δÞ. We then
deﬁne the INB for this model as
INB¼100 π1π2ð Þδ ð1Þ
where 100 is the selected willingness to pay. Note that this
threshold is used for illustrative purposes as the effectiveness
measure is probability of a cure rather than quality-adjusted life
years (QALYs).
For this model, we report PSA simulations for S ¼ 10 in
Table 1. Each parameter is simulated from its distribution and
then each simulated row is used to calculate the INB using Eq. (1).
The mean and variance of the INB are calculated as μθ¼ 4:5 and
σ2θ¼722.
Using an EVPPI analysis, we found that when reducing
uncertainty in π1, the probability of a cure for treatment 1 has
the highest value. Therefore, we design a trial where treatment 1
is given to 20 people and observe how many patients respond.
This implies a binomial sampling distribution for the future
study: XBinomialð20, π1Þ.
To calculate the EVSI, we determine the INB conditional on
ϕ¼π1. In this example, we have used the EVPPI calculation
method developed by Strong et al. [29] to calculate INBϕ, and
the values are given in Table 1. The variance of INBϕ is then
calculated as σ2ϕ¼391:
The ﬁnal element required for the moment matching
method is the posterior variance estimated using nested
sampling. For illustrative purposes, we set Q ¼ 3. To begin,
we order the observed π1 values, which produces the following
vector:
0:26, 0:27, 0:30, 0:37, 0:47, 0:50, 0:51, 0:53, 0:59, 0:76ð Þ:
We then select the 2.5th, 5.5th, and 7.5th elements in this
ordered list. Each of these values is used to simulate a potential
future sample from the sampling distribution of X. Each future
Table 1 – The PSA samples for the toy example along with the elements required to estimate the EVSI.
s e1 e2 c INB INBϕ INBnϕ max
1 0.30 0.70 4.5 44 24 22 0
2 0.47 0.93 36.8 10 3 3 0
3 0.26 0.32 15.4 21 29 26 0
4 0.50 0.58 1.9 10 1 0 0
5 0.27 0.57 0.1 31 28 26 0
6 0.53 0.36 26.4 44 5 4 4
7 0.59 0.39 6.6 27 12 10 10
8 0.37 0.44 11.4 19 16 15 0
9 0.76 0.37 30.2 9 33 29 29
10 0.51 0.40 0.9 10 3 2 2
Mean 0.46 0.51 0.6 4.5 4.5 4.5 4.6
Var 0.01 0.04 377 722 391 316 —
Var, variable.
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posterior INB. In this example, 100 simulations from the posterior
of π1 are combined with 100 simulations of π2 and δ to calculate
the posterior INB and its variance. Table 2 demonstrates this
process giving the variance of the posterior INB for each sample
and the average posterior variance σ2X as 406.
We can now combine all the elements to rescale the INBϕ
values,
INBn¼ INBϕð4:5Þﬃﬃﬃﬃﬃﬃﬃﬃ
391
p
  ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
722406
p
þ 4:5ð Þ:
These values are given in Table 1. Finally, the EVSI is
estimated using moment matching, as
EVSI¼ 1
10
4þ10þ29þ2ð Þmax 0,4:5f g¼4:6
This example is illustrative of the moment matching method;
in practice, a large PSA simulation size should be used, ideally in
excess of 1000.Calculating the EVSI: A New Chemotherapy Drug
To demonstrate the moment matching method and investigate
the optimal value for Q, we extend a model developed to compare
a new chemotherapy treatment against the standard of care [21].
In this model, the two treatments differ only in the number of
side effects experienced, with the new drug aiming to reduce it.
This in turn reduces the cost of treating side effects, as they
require additional treatment, and increases the patient’s quality
of life.
There are 14 model inputs related to the cost and QALYs
associated with experiencing side effects and the probability of
experiencing side effects on either treatment. The progression of
the side effects is modeled using a four state Markov model withTable 2 – The posterior variance of the INB for the
three different values of the parameter under
investigation ϕ = e1.
q ϕ¼e1 Xq σ2q
1 0.285 4 416
2 0.485 9 372
3 0.52 10 430
Mean — — 406further details provided in the supplementary material, along
with model code.
A Trial Investigating Side Effects of Chemotherapy Treatment
To gather more information for this model, we designed a trial
where both treatments would be given to 150 patients. In the
main, this trial will inform the probability of side effects for each
treatment. As a secondary outcome, we also studied the disease
progression of any of the patients experiencing side effects. This
directly informed the transition probabilities of the Markov
model for side effects treatment. An EVPPI analysis demonstrated
that gaining perfect information about these parameters would
explain 90% of the model uncertainty. For simplicity, we assumed
complete compliance with the treatment and full follow-up. A
full description of the sampling distributions used for the EVSI
analysis is given in the supplementary material.
The Optimal Number of Nested Samples
To ﬁnd the optimal number of nested samples, we ﬁxed the total
number of simulations used to estimate the EVSI. Clearly, as with all
simulation-based methods, we increased the accuracy of the EVSI
estimate by increasing the total number of simulations. However, in
ﬁxing the total computational cost, we determined the relative
importance of increasing Q versus increasing the number of
simulations from the posterior distribution of the model inputs.
We used two sizes of nested simulation: 500,000 with a
computation time between 108 and 129 seconds for one EVSI
estimate and 5000 with a computation time between 9 and 17
seconds. We then considered 8 different values of Q ¼ 20,30,
…,100, where 20 is below the recommended lower limit for Q [10].
Because the EVSI is estimated by simulation, it is subject to
random variance. Therefore, we calculated the EVSI 200 times for
each combination of Q and simulation size. This allowed us to
calculate the variance of the EVSI estimate for each combination
(Fig. 2) and the bias (Fig. 3). To calculate the bias, we estimated
the EVSI using nested simulation with S ¼ 100,000 and R ¼
100,000 with a computational cost of around 60 days.
Figure 2 demonstrates that larger Q values produced more
precise EVSI estimates as the variance is smaller. This is true for
both 500,000 and 5000 simulations although the variance seems
to plateau earlier for 5000, implying that increasing Q is less
important when the number of posterior simulations is not
sufﬁcient to estimate the posterior of θ. Therefore, computa-
tional effort should be used to increase Q and not R, the number
of simulations for each posterior. Clearly, the variance of the
estimated EVSI was lower with a greater number of simulation.
Fig. 2 – The variance of the EVSI estimate for each
combination of Q and the total number of simulations. Blue
crosses represent the variance when the number of
simulations is equal to 5 000 and red dots for 500 000.
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accurate EVSI estimates. Nevertheless, the moment matching
method seems to have a slight upward bias, reducing as Q
increases. Note that the bias is large for Q ¼ 20, conﬁrming that
the moment matching method should be used only with Q 4 30.
In light of this analysis, Q should be chosen in the following
manner. First, determine the number of simulations R required to
characterize the posterior distribution of θ and the total number
of simulations available to estimate the EVSI. Then, Q should be
equal to the total number of simulations divided by R. For
example, if 50,000 posterior simulations can be used to estimate
the EVSI and R ¼ 1000, then Q ¼ 50 nested simulations should
be used.Fig. 3 – The bias of the EVSI estimate for each combination of
Q and the total number of simulations. Blue crosses
represent the bias when the number of simulations is equal
to 5 000 and red dots for 500 000.As a ﬁnal comment, note that the INB values are calculated
using the difference between the PSA variance of the INB σ2θ and
the mean posterior variance σ2x, from Eq. (2). Therefore, accurately
estimating σ2x using nested simulations is useless if σ2θ is poorly
estimated. Thus, the PSA simulations size S must be relatively
large. In addition, the required accuracy of the estimates of σ2x
and σ2θ actually depends on the size of the EVSI. For a small EVSI,
the posterior variance is close to the prior variance meaning that
of σ2ϕσ2θ is small. As both variances are estimated by simulation,
the sampling variation could be larger than the true difference,
leading to inaccurate EVSI estimates. Therefore, the moment
matching method should be used only for studies where the
EVPPI for ϕ is high.Conclusions
In this paper, we have presented an efﬁcient Monte Carlo
estimation method for the EVSI. This method signiﬁcantly
reduces the number of nested simulations required to accurately
estimate the EVSI. This maintains the ﬂexibility and comprehen-
sibility of the nested Monte Carlo method while reducing com-
putational time. The moment matching method was presented in
theoretical terms alongside an illustrative worked example.
Finally, we explored the optimal number of nested samples
required to accurately estimate the EVSI. In general, the number
of nested samples should be taken as large as possible, while
maintaining a feasible computational cost and ensuring that
the posterior distribution for the model inputs is adequately
captured.
Another advantage of this efﬁcient Monte Carlo method is
that general purpose software has been developed to perform
these EVSI calculations [34]. Early results also indicate that this
method can be extended to estimate EVSI across different sample
sizes with no additional computational cost, meaning that the
EVSI could be used as a tool for trial design within a realistic
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